头孢吡肟致免疫性血小板减少症 1 例
A Case of Cefepime-Induced Immune Thrombocytopenia.
机构信息
Maine Medical Center, Portland, Maine, USA.
MaineHealth Cancer Care, South Portland, ME, USA.
出版信息
J Clin Pharm Ther. 2022 Apr;47(4):556-558. doi: 10.1111/jcpt.13546. Epub 2021 Nov 2.
WHAT IS KNOWN AND OBJECTIVE
Drug-induced immune thrombocytopenia (DITP) is a rare adverse event. It is often diagnosed using clinical risk criteria, but this can create diagnostic uncertainty.
CASE DESCRIPTION
A 35-year-old man with disseminated Serratia marcescens infection developed severe thrombocytopenia. A drug-dependent platelet-reactive antibody test demonstrated cefepime-dependent platelet-reactive antibodies which confirmed the diagnosis of DITP.
WHAT IS NEW AND CONCLUSION
We describe the first case of cefepime-induced DITP confirmed by a drug-dependent platelet-reactive antibody test. To our knowledge, this is the first proven example of DITP in a fourth-generation cephalosporin.
已知和目的
药物诱导的免疫性血小板减少症（DITP）是一种罕见的不良反应。它通常使用临床风险标准进行诊断，但这可能会造成诊断的不确定性。
病例描述
一名 35 岁男性患有播散性粘质沙雷氏菌感染，出现严重血小板减少症。药物依赖性血小板反应性抗体检测显示头孢吡肟依赖性血小板反应性抗体，这证实了 DITP 的诊断。
新发现和结论
我们描述了首例通过药物依赖性血小板反应性抗体检测证实的头孢吡肟引起的 DITP。据我们所知，这是首例在第四代头孢菌素中证实的 DITP 病例。
Zotero 插件